Clinical stage specialty pharmaceutical company Taris Biomedical has begun patient dosing in its second Phase II study with LiRIS, for the treatment of interstitial cystitis (IC).

LiRIS is designed to constantly deliver lidocaine to the bladder of IC patients over an extended period to relieve the painful symptoms associated with the disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“LiRIS is designed to constantly deliver lidocaine to the bladder of IC patients over an extended period to relieve the painful symptoms associated with the disease.”

Queens University, Canada, urology professor and trial principal investigator Dr Curtis Nickel said; “TARIS’ first Phase II study provided important insights into both the disease and the benefit of LiRIS relative to placebo in this patient population. This new study incorporates these learnings.”

The multicentre, randomised Phase II clinical study is designed to assess the safety and efficacy of LiRIS in around 124 patients with interstitial cystitis.

Patients successfully completing the placebo-controlled trial will be eligible for participation in a following open-label extension arm, and will be administered LiRIS.

This study is scheduled to be conducted in up to 15 investigational sites across US and Canada.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Taris president and CEO Dr Purnanand Sarma said; “We anticipate this new study will provide necessary data that will enable us to design a successful registration programe. Interstitial cystitis continues to be a significant unmet medical need, and we believe our technology can fundamentally change the treatment of this debilitating condition.”